Cite
Longitudinal Correlative Profiles of Responders, Nonresponders, and Those with Relapse on Treatment with Teclistamab in the Phase 1/2 MajesTEC-1 Study of Patients with Relapsed/Refractory Multiple Myeloma
MLA
Vishwamitra, Deeksha, et al. “Longitudinal Correlative Profiles of Responders, Nonresponders, and Those with Relapse on Treatment with Teclistamab in the Phase 1/2 MajesTEC-1 Study of Patients with Relapsed/Refractory Multiple Myeloma.” Blood, vol. 142, no. 1, Number 1 Supplement 1, Nov. 2023, p. 455. EBSCOhost, https://doi.org/10.1182/blood-2023-173550.
APA
Vishwamitra, D., Skerget, S., Cortes, D., Perova, T., Lau, O., Davis, C., Guo, Y., Miao, X., Stephenson, T., Hodin, C., Uhlar, C., Trancucci, D., Chastain, K., Bahlis, N. J., Van De Donk, N. W. C. J., & Verona, R. (2023). Longitudinal Correlative Profiles of Responders, Nonresponders, and Those with Relapse on Treatment with Teclistamab in the Phase 1/2 MajesTEC-1 Study of Patients with Relapsed/Refractory Multiple Myeloma. Blood, 142(1, Number 1 Supplement 1), 455. https://doi.org/10.1182/blood-2023-173550
Chicago
Vishwamitra, Deeksha, Sheri Skerget, Diana Cortes, Tatiana Perova, Onsay Lau, Cuc Davis, Yue Guo, et al. 2023. “Longitudinal Correlative Profiles of Responders, Nonresponders, and Those with Relapse on Treatment with Teclistamab in the Phase 1/2 MajesTEC-1 Study of Patients with Relapsed/Refractory Multiple Myeloma.” Blood 142 (1, Number 1 Supplement 1): 455. doi:10.1182/blood-2023-173550.